Light therapy in medicine: where do we stand?
Open accessThe DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index; none of the 204 sources its claims cite is checked for support yet.
Abstract
Light therapy encompasses a broad spectrum of interventions, ranging from established clinical applications to emerging and experimental indications. This review evaluates the current state of light therapy across medical disciplines, emphasizing the need to distinguish validated clinical uses, exploratory findings, and preclinical research. The biological effects of light therapy are diverse, with mechanisms depending on wavelength, route of delivery, and biological target. Ocular exposure to bright light primarily acts through the circadian system to influence mood and sleep, whereas peripheral photobiomodulation (PBM) and ultraviolet (UV) phototherapy act directly on local tissues to promote healing. Mitochondrial activation is a proposed general mechanism, but its centrality is likely modality- and context-dependent. Robust clinical evidence supports bright light therapy for seasonal affective disorder (SAD) and UV-B for psoriasis, while moderate evidence exists for dermatological and sleep applications. For delirium, bright light therapy has shown promise in small-scale studies, but large-scale confirmatory clinical trials are still lacking. Other reported uses, including pain management, ischemia-reperfusion (IR) injury, clotting disorders, and infectious lung injury, are largely supported by preclinical and mechanistic studies, particularly those involving intense light that elicits the circadian core protein Period 2 (PER2). The clinical relevance of these mechanisms remains under investigation. Overall, light therapy remains safe when used according to established protocols. This review aims to provide a nuanced synthesis of the field, highlighting both the promise and the limitations of light therapy and emphasizing the importance of the evidence hierarchy in guiding clinical translation and research priorities.
Overview
CoChat Summary
## TL;DR
This review argues that “light therapy” is not one thing but several biologically distinct interventions, with strong evidence for some uses (notably SAD and neonatal phototherapy) and mostly preliminary or preclinical evidence for others. It emphasizes that timing, wavelength, dose, and route of delivery matter, and that many promising organ-protection findings hinge on circadian mechanisms, especially PER2.
## Key findings
- For seasonal affective disorder (SAD), intense light therapy is reported as highly effective: standard treatment is 10,000 lux for ~30 min/day, and meta-analysis is described as showing ~70–80% response rates in well-selected patients.
- For neonatal hyperbilirubinemia, phototherapy is described as first-line treatment using blue light in the 460–490 nm range; the review states that large randomized controlled trials and meta-analyses confirm efficacy and safety.
- For wound healing, a meta-analysis is said to show significant benefits, with collagen formation effect size +2.78, plus improved healing rate and tensile strength.
- For organ protection, the review highlights preclinical and preliminary human findings: in bacterial pneumonia models, 0% survival in mice lacking ATII-specific PER2 versus 85% survival in controls; in a preliminary human spine-surgery study, 30 min of sunrise light for 5 days increased plasma ANGPTL4 and decreased troponin versus historical controls/baseline.
## Methods
- Narrative review/synthesis of current research on light therapy’s mechanisms, efficacy, safety, and clinical applications across multiple domains.
- The paper distinguishes major modalities, including visual/photoneuromodulatory light therapy versus peripheral PBM and UV phototherapy, and discusses evidence separately by indication.
- Evidence base appears to include meta-analyses, randomized controlled trials, pilot studies, preclinical animal experiments, and one preliminary human study; no systematic search strategy or pooled analysis is stated in the provided text.
## Limitations
- The paper states that evidence for several uses is still limited: delirium evidence is from small trials, pain management evidence is often moderate or preliminary, and organ-protection applications are largely preclinical/mechanistic; this is explicitly stated in the text.
- It also states that larger, more definitive, multi-center, or rigorous trials are needed for PMDD, TBI/PTSD sleep disturbance, substance use disorders, wound healing standardization, and long-term safety.
- Evident from the text: the review is broad and heterogeneous, spanning many modalities and indications with different endpoints, which makes direct comparison difficult; the paper itself notes the need not to conflate modalities and evidence levels.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures













Verification
Claims the paper makes
0 Valid · 13 Not valid · 207 Not checked · 70 Own results and interpretations
In the paper
“Phototherapy is the first-line treatment for neonatal hyperbilirubinemia (82),”
- Also stated in: § Neonatal phototherapy for hyperbilirubinemia · plain
“Phototherapy is the first-line treatment for neonatal hyperbilirubinemia (82), a common and potentially serious condition in newborns caused by elevated levels of unconjugated bilirubin.”
§ Light therapy in medicine: where do we stand? > Neonatal phototherapy for hyperbilirubinemia
What the sources say
- Not matchedcites [82] American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114: 297- 316. 10.1542/peds.114.1.297 15231951
We don’t have this paper’s reference list.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Neonatal phototherapy for hyperbilirubinemia · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Robust clinical evidence supports bright light therapy for seasonal affective disorder (SAD) and UV-B for psoriasis, while moderate evidence exists for dermatological and sleep applications.”
§ Light therapy in medicine: where do we stand? > Abstract Light therapy encompasses a broad spectrum of interventions, ranging from established clinical applications to emerging and experimental indications. This review evaluates the current state of light therapy across medical disciplines, emphasizing the need to distinguish validated clinical uses, exploratory findings, and preclinical research. The biological effects of light therapy are diverse, with mechanisms depending on wavelength, route of delivery, and biological target. Ocular exposure to bright light primarily acts through the circadian system to influence mood and sleep, whereas peripheral photobiomodulation (PBM) and ultraviolet (UV) phototherapy act directly on local tissues to promote healing. Mitochondrial activation is a proposed general mechanism, but its centrality is likely modality- and context-dependent. Robust clinical evidence supports bright light therapy for seasonal affective disorder (SAD) and UV-B for psoriasis, while moderate evidence exists for dermatological and sleep applications. For delirium, bright light therapy has shown promise in small-scale studies, but large-scale confirmatory clinical trials are still lacking. Other reported uses, including pain management, ischemia-reperfusion (IR) injury, clotting disorders, and infectious lung injury, are largely supported by preclinical and mechanistic studies, particularly those involving intense light that elicits the circadian core protein Period 2 (PER2). The clinical relevance of these mechanisms remains under investigation. Overall, light therapy remains safe when used according to established protocols. This review aims to provide a nuanced synthesis of the field, highlighting both the promise and the limitations of light therapy and emphasizing the importance of the evidence hierarchy in guiding clinical translation and research priorities.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Intrinsically photosensitive retinal ganglion cells (ipRGCs), which express melanopsin, send light information to the suprachiasmatic nucleus (SCN), the brain’s master clock, thereby synchronizing the body’s internal biological rhythms (16).”
§ Light therapy in medicine: where do we stand? > Mechanisms of light therapy Light therapy has emerged as a promising intervention across various medical fields, operating through mechanisms that modulate biological rhythms and enhance cellular function. While interaction with mitochondrial proteins, particularly activation of cytochrome c oxidase by red or near-infrared (NIR) light in PBM, has been proposed as one mechanism, it should not be overstated as the primary or universal pathway. Other mechanisms underlying central-based light therapy are well described and often better supported by experimental evidence, including modulation of circadian rhythms, regulation of melatonin secretion, and activation of diverse cellular chromophores and photoreceptors. As such, central or peripheral light-based therapies involve a variety of proteins, such as opsins, and macrocyclic organic compounds, or flavins and porphyrins, each relying on distinct photoactivation mechanisms to initiate downstream signaling cascades. Regarding peripheral light-based therapy, specific wavelengths of light can activate important pathways, such as the Wnt/β-catenin and ERK pathways, which influence cell proliferation and growth (14). These signaling mechanisms translate light energy into biological responses that promote healing and tissue regeneration. This increased energy availability supports cellular repair and regeneration processes. Similarly, PBM promotes oxidative phosphorylation while simultaneously inhibiting glycolysis in microglia, suggesting a metabolic reorientation from glucose-dependent to mitochondrial-dependent energy production (15). In contrast, central-based light therapy acts through non-image-forming visual pathways that influence circadian rhythms. Intrinsically photosensitive retinal ganglion cells (ipRGCs), which express melanopsin, send light information to the suprachiasmatic nucleus (SCN), the brain’s master clock, thereby synchronizing the body’s internal biological rhythms (16). Although ipRGCs are part of the visual system, they do not contribute to image formation but are instead specialized for circadian photoentrainment and other non-image-forming visual functions.
What the sources say
- Not matchedcites [16] Yuan M Liu H Zhu R Retinal light perception and biological rhythms: The role of light in sleep and mood from an ophthalmic perspective (Review). Mol Med Rep 2026; 33: 16. 10.3892/mmr.2025.13726 41170746 PMC12587107
We don’t have this paper’s reference list.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
None of the sources cited for this claim could be matched to a paper, so there is nothing to check it against.
In the paper
“These cells express the photopigment melanopsin, which is maximally sensitive to blue light at approximately 480 nm (17,18).”
§ Light therapy in medicine: where do we stand? > The melanopsin/ipRGC pathway in circadian phototransduction
What the sources say
- Not matchedcites [17] Berson DM Dunn FA Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. Science 2002; 295: 1070- 3. 10.1126/science.1067262 11834835
We don’t have this paper’s reference list.
- Not matchedcites [18] Hattar S Liao HW Takao M Melanopsin-containing retinal ganglion cells: architecture, projections, and intrinsic photosensitivity. Science 2002; 295: 1065- 70. 10.1126/science.1069609 11834834 PMC2885915
We don’t have this paper’s reference list.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“Regarding peripheral light-based therapy, specific wavelengths of light can activate important pathways, such as the Wnt/β-catenin and ERK pathways, which influence cell proliferation and growth (14).”
§ Light therapy in medicine: where do we stand? > Mechanisms of light therapy Light therapy has emerged as a promising intervention across various medical fields, operating through mechanisms that modulate biological rhythms and enhance cellular function. While interaction with mitochondrial proteins, particularly activation of cytochrome c oxidase by red or near-infrared (NIR) light in PBM, has been proposed as one mechanism, it should not be overstated as the primary or universal pathway. Other mechanisms underlying central-based light therapy are well described and often better supported by experimental evidence, including modulation of circadian rhythms, regulation of melatonin secretion, and activation of diverse cellular chromophores and photoreceptors. As such, central or peripheral light-based therapies involve a variety of proteins, such as opsins, and macrocyclic organic compounds, or flavins and porphyrins, each relying on distinct photoactivation mechanisms to initiate downstream signaling cascades. Regarding peripheral light-based therapy, specific wavelengths of light can activate important pathways, such as the Wnt/β-catenin and ERK pathways, which influence cell proliferation and growth (14). These signaling mechanisms translate light energy into biological responses that promote healing and tissue regeneration. This increased energy availability supports cellular repair and regeneration processes. Similarly, PBM promotes oxidative phosphorylation while simultaneously inhibiting glycolysis in microglia, suggesting a metabolic reorientation from glucose-dependent to mitochondrial-dependent energy production (15). In contrast, central-based light therapy acts through non-image-forming visual pathways that influence circadian rhythms. Intrinsically photosensitive retinal ganglion cells (ipRGCs), which express melanopsin, send light information to the suprachiasmatic nucleus (SCN), the brain’s master clock, thereby synchronizing the body’s internal biological rhythms (16). Although ipRGCs are part of the visual system, they do not contribute to image formation but are instead specialized for circadian photoentrainment and other non-image-forming visual functions.
What the sources say
- Not matchedcites [14] Mpanza M Abrahamse H Crous A. Photobiomodulation-induced activation of Wnt signaling enhances differentiation of adipose-derived stem cells into tenocytes: Mechanistic insights into regenerative signaling pathways. Cell Transplant 2025; 34: 9636897251372397. 10.1177/09636897251372397 41307143 PMC12660645
We don’t have this paper’s reference list.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
154 more claims
Create a free account to see all 290 claims and every source verdict.
- It may state two separate claims as one. 122
- Probably not a substantial claim. 16
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Research works printed but not linked: 2
- [47]Doskaliuk B. Phototherapy: cutaneous and systemic rejuvenation. Anti-Aging Eastern Europe 2025; 4: 108- 11.
- [122]Chung EH Son JW Eun YS A Novel, Hand-Held, and Low-Level Light Therapy Device for the Treatment of Acne Vulgaris: A Single-Arm, Prospective Clinical Study. Dermatol Ther 2023; 2023: 8846620.
Metadata
- Authors
- Oyama, Y., Witowski, A., Adamzik, M., Bartels, K., & de la Garza Eckle, T.
- Affiliations
- Oita University (JP)
- University Hospitals of the Ruhr-University of Bochum (DE)
- University of Michigan (US)
- Venue
- Annals of Translational Medicine
- Publisher
- AME Publishing Company
- Published
- 2026-06
- Volume
- 14
- Issue
- 3
- Pages
- 35-35
- ISSN
- 2305-5839 (ISSN-L)
- 2305-5847
- PMC
- PMC13349728
- OpenAlex
- W7166669340
- Cited by
- 0
- References
- 0
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Annals of Translational Medicine (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- Funders
- National Heart, Lung, and Blood Institute (R56HL156955, R01HL122472)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Laser Applications in Dentistry and Medicine
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
- Health Sciences › Medicine › Complementary and alternative medicine › Biofield Effects and Biophysics
- Keywords
- phototherapy, low-level laser therapy, bright light therapy, circadian rhythm, seasonal affective disorder, ultraviolet therapy, psoriasis, mitochondrial activation, Per2, delirium, pain management, ischemia-reperfusion injury, clotting disorders, lung injury, evidence hierarchy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Light therapy in medicine: where do we stand? https://app.cochat.ai/papers/10.21037/atm-2026-0041
- The paper
- Oyama, Y., Witowski, A., Adamzik, M., Bartels, K., & de la Garza Eckle, T. (2026). Light therapy in medicine: where do we stand? Annals of Translational Medicine. https://doi.org/10.21037/atm-2026-0041
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.